Stockreport

Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development

Synlogic, Inc.  (SYBX) 
Last synlogic, inc. earnings: 3/12 04:19 pm Check Earnings Report
PDF – Data demonstrate statistically significant biomarker activity at well-tolerated dose in PKU patients –– Plan to initiate bridging study with new oral solid formulation [Read more]